Projet CaReSyAn (Horizon 2020, appel à projets 2017)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : CLOSED

Successfully combatting a complex disease requires multi-disciplinary and methodically well-trained scientists. CaReSyAn strives to accomplish exactly this: we will train scientists to successfully integrate proteomics, clinical, experimental and bioinformatical analyses to enhance the understanding, diagnosis and therapy of the cardiorenal syndrome (CRS). CRS comprises disorders of the heart, vessels and kidneys, including the increased development of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). With ~45% of all deaths in CKD patients caused by CVD, the socio-economic burden of CRS is extremely high. CaReSyAn will train scientists in a close cooperation between academia, SME and industry partners. Key objectives are to provide: 1) Excellent scientific training on CRS pathology, integrating clinical/mechanistic knowledge with technological skills (animals and in vitro, molecular and functional studies, proteomics and bioinformatics) to generate innovative insights triggering the understanding, diagnosis and treatment of the CRS; 2) Excellent complementary skills in personal and career development as well as business training required to extend beyond scientific research; and 3) Exposure to both academic and non-academic environments, required to build bridges between researchers and entrepreneurs and support the future translation of research findings in innovative products and services. CaReSyAn builds on already available patient cohorts, advanced technologies and established cooperations. CaReSyAn is complementary to ongoing European programs focusing solely on CKD or CVD and strives to synergistically improve structural training on European level. CaReSyAn will nurture the development of young, broadly-trained scientists able to successfully bridge clinical with basic research as well as academia and industry. This is a cornerstone in effectively combatting complex diseases as CRS, a major killer of this century.

Mots clés : cardiorenal syndrome, chronic kidney disease, calcification, pathological mechanisms, clinical, animal, experimental disease models

Participants :
- Medical University of Vienna (Autriche) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 255934.08 €
- Bayer (Germany) (Allemagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Hospital Universitario Fundación Jiménez Díaz (Espagne) — Partner, organization partner, Recherche, subvention : 0.0 €
- KU Leuven (Belgique) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- European society for artificial organs (Autriche) — Partner, organization partner, Organismes publics (hors enseignement & recherche), subvention : 0.0 €
- Mosaiques Diagnostics and Therapeutics (Germany) (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 249216.48 €
- DSM (Netherlands) (Pays-Bas) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 0.0 €
- Fresenius (Germany) (Allemagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Universitätsklinikum Aachen (Allemagne) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 747649.44 €
- Karolinska Institutet (Suède) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 263659.32 €
- Biomedical Research Foundation of the Academy of Athens (Grèce) — Partner, beneficiary, Recherche, subvention : 242386.92 €
- RD Néphrologie (France) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 0.0 €
- Institut national de la santé et de la recherche médicale (France) — Partner, beneficiary, Recherche, subvention : 262875.6 €
- Maastricht University (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 510748.56 €
- Université de Montpellier (France) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 262875.6 €